H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Asensus Surgical (ASXC – Research Report) today and set a price target of $4.00. The company's shares closed last Wednesday at $0.44, close to its 52-week low of $0.41. According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 2.8% and a 34.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals, Corvus Pharmaceuticals, and Janux Therapeutics Inc. Currently, the analyst consensus on Asensus Surgical is a Moderate Buy with an average price target of $4.00. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $3.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-asensus-surgicals-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral